By Roy, founder Last updated 12/09/2026
Short answer: nothing has changed yet. A private applicant has asked the Therapeutic Goods Administration (TGA) to delete melatonin's pharmacist-only entry and replace it with an open-shelf pharmacy entry for adults 18 and over. That request went to the TGA's expert scheduling committee in March 2026. As at this update, no decision has been published, interim or final, and today's rules apply in full.
This page sets out what is legal to buy right now, what the proposal would actually change, how a proposal becomes an enforceable rule (a longer road than it sounds), and what happened in New Zealand, which the TGA's own paperwork names as the reason for the request.
What's legal to buy today, in full
Start here, because this is the part a reader can't afford to get wrong.
Melatonin's default position in Australia is Schedule 4, prescription only. The Poisons Standard entry reads: "MELATONIN for human use, except when included in Schedule 3." That covers the overwhelming majority of melatonin products, doses and people. No pharmacist can hand it over without a script.
There are exactly two exceptions, both sitting inside Schedule 3, "Pharmacist Only Medicine." A pharmacist can supply melatonin without a script, but only if it fits one of these two lanes, quoted directly from the current Poisons Standard, as reproduced on the TGA's own site:
> MELATONIN in: > (a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of [...] poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or > (b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units.
In plain terms: a modified-release product at 2mg or less, for someone 55 or over, in a pack of 30 tablets or fewer, sold for short-term use; or an immediate-release product at 5mg or less, for jet lag only, for anyone 18 or over, in a pack of 10 doses or fewer. Nothing else qualifies. A 40-year-old asking a pharmacist for melatonin after a run of bad nights falls outside both lanes and needs a script, the same as anyone under 55 buying it for general sleep support.
There is no Schedule 2 melatonin entry in force today. Schedule 2 is the open-shelf category. It does not exist for melatonin in Australia right now, whatever the proposal below might eventually change.
What the 2026 proposal would actually change
A private applicant, not named in the public documents, has asked the TGA to delete the Schedule 3 entry above entirely and replace it with a new Schedule 2 entry. The TGA's own March 2026 consultation paper describes it directly:
> Under the proposal, the Pharmacist-only medicine (Schedule 3) entry for melatonin would be deleted, and a Pharmacy medicine (Schedule 2) entry for the substance would be created. The new Schedule 2 entry would expand melatonin's dosage forms, strengths and access for those aged 18 years and over for monotherapy for the short-term treatment of [...] poor quality of sleep.
The proposed new entry, quoted from the same document:
> MELATONIN in: > (a) modified release dose units containing 2 mg or less of melatonin for monotherapy for the short-term treatment of [...] poor quality of sleep for adults aged 18 or over, in packs containing not more than 30 days' supply; or > (b) immediate release dose units containing 3 mg or less of melatonin for monotherapy for the short-term treatment of [...] poor quality of sleep for adults aged 18 or over, in packs containing not more than 30 days' supply; or > (c) immediate release dose units containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 days' supply.
Three changes stand out. The age floor for general short-term use would drop from 55 to 18. A new immediate-release option appears at 3mg or less, with no equivalent in today's rules. And "tablets" becomes "dose units" while pack counts become "days' supply", which would allow pastilles, capsules and gels, not just tablets.
The proposal would also delete the Appendix H entry that currently lets Schedule 3 melatonin be advertised, because Schedule 2 medicines are already permitted to be advertised without that separate carve-out.
Who it would, and wouldn't, cover
If this proposal became law exactly as written, an adult 18 or over could buy an appropriate melatonin product straight off a pharmacy shelf, without asking a pharmacist and without a script, for either short-term sleep support or jet lag, inside the dose and pack limits above.
It would not make melatonin a supermarket item. Schedule 2 still means pharmacy only, just not behind the counter. Dose and pack limits stay. Nobody under 18 is covered, at any dose. And it would not apply to melatonin gummies built for the US market, which are formulated to different dose and pack rules than anything proposed here.
The applicant's own stated reasoning, reported by the TGA and not independently verified as a TGA finding, is that melatonin has a "favourable safety profile, low toxicity and mild, self-limiting side effects", and that easier legal access would reduce the number of people buying unregulated melatonin online. For scale, the same document reports that as of late 2025, 59 medicines on Australia's therapeutic goods register contained melatonin, and the national adverse event database held 115 reports naming a melatonin-containing product, with melatonin the single suspected medicine in 68 of those.
A proposal is not a decision. Here is the actual difference.
This is the part most coverage of TGA scheduling changes skips, and it's the gap between an accurate answer and a wrong one. A change to the Poisons Standard goes through three formal stages, not one:
1. Proposal. Anyone, including a private individual or a company, can apply to have a substance's schedule changed. The TGA opens the application for public comment, then refers it to the Advisory Committee on Medicines Scheduling (ACMS), which weighs the evidence and submissions. 2. Interim decision. After the committee meets, the Delegate publishes an interim decision: real, published, with specific wording and a proposed effective date, but still open for a further round of submissions. 3. Final decision. After that consultation, the Delegate publishes a final decision, which can confirm, adjust or drop the interim wording, and sets the date the new rule actually takes effect.
Only the final decision changes what is legal. A proposal is a request. An interim decision is a considered but still-open draft. Neither is a rule change anyone can act on.
Melatonin's 2026 proposal sits at stage one. It has been to committee. No interim decision has been published.
The precedent: how long the last melatonin change actually took
Melatonin has been through this exact process once before, and the timeline is the best available evidence for how long stage one to a working rule actually takes.
In 2020, a proposal to create the current 55-and-over, 2mg modified-release Schedule 3 lane went to the same committee (ACMS #29, meeting March 2020). The Delegate's interim decision was published 10 June 2020, roughly three months after the meeting, with a proposed effective date of 1 October 2020. A second round of public submissions followed, specifically on that proposed date, because the first round hadn't addressed timing. The Delegate then published a final decision on 28 September 2020, roughly three and a half months after the interim decision, which made a small wording change and pushed the effective date out to 1 June 2021, a further eight months on.
Add it up: committee meeting to interim decision, then to final decision, then to the rule actually taking effect, was well over a year start to finish. That is how long this kind of change takes when everything runs on the TGA's own indicative timetable. The current process is running well behind even that.
Where the process actually stands, and why "imminent" isn't right
The TGA's own published timetable for a March 2026 committee meeting projected an interim decision by around June 2026, a further submission period through July, a final decision in August, and an effective date in October 2026. If that timetable had held, an interim decision on melatonin would already be public.
It is not. Checked directly against the TGA's live records as at 12 September 2026:
- The TGA's interim decisions index lists its most recent entry as the outcome of a June 2025 committee meeting, published 9 June 2026, roughly twelve months after that meeting took place. Nothing from the March 2026 meeting that considered melatonin appears on the list.
- The TGA's final decisions index carries no melatonin entry either.
- The currently in-force Poisons Standard still carries the old Schedule 3 wording, with no Schedule 2 melatonin entry anywhere in it, which would not be the case if a final decision had already taken effect.
- The TGA's own consumer-facing page on melatonin regulation still describes only the existing rules, with no mention of a pending change.
The pattern across three other recent committee cycles backs this up. A November 2024 meeting produced an interim decision roughly seven months later. A March 2025 meeting took roughly nine months. A June 2025 meeting took roughly twelve months. Each cycle has taken longer than the one before it, not shorter.
Extrapolating that trend, an interim decision on melatonin looks more plausible in late 2026 or 2027 than in the near term. That is an extrapolation from the committee's own recent track record, not a published TGA date, and it should be read as one. Nobody, including the TGA, has stated a date.
New Zealand: what actually changed, and why the TGA points to it
New Zealand is the other half of this story, and it is the TGA's own stated reason for the proposal.
New Zealand's medicines regulator, Medsafe, changed melatonin's classification on 10 October 2025. In its own words: "A change to the classification of melatonin on 10 October 2025 enables approval of products that may be supplied to adults aged 18 years and over without a consultation with a doctor or pharmacist." (Medsafe)
That followed a June 2025 announcement by New Zealand's Associate Minister of Health that the government would let pharmacies sell approved melatonin products without a doctor or pharmacist consultation first. (RNZ) Companies applied for approval from July 2025, and Medsafe approved the first qualifying products in September 2025, ahead of the October classification change taking effect. (Medsafe)
The TGA's own March 2026 consultation document states plainly that the Australian proposal is designed to match this. Quoted directly: "The applicant's proposal will also bring Australia's regulation of melatonin in line with that of New Zealand, which was amended as of October 2025 to allow for the supply of the substance to adults aged 18 or over, without the need for a prescription." (TGA consultation document)
Worth being precise about what New Zealand's rule allows, because "over the counter in NZ" undersells the limits. It applies to approved products only, in original manufacturer packaging, for adults 18 and over: immediate-release at 5mg or less for jet lag (10 days' supply), or immediate-release at 3mg or less, or modified-release at 2mg or less, for short-term sleep support (30 days' supply). A separate, older pharmacist-supply category still exists for adults 55 and over on longer-term supply, and unapproved melatonin still needs a prescription to bring in. (Medsafe)
So New Zealand did not deregulate melatonin outright. It moved a defined, dose-limited category from pharmacist-only to pharmacy-shelf, for adults, using approved products. That is closer to what Australia's 2026 proposal describes than the looser "OTC now" framing that circulates online.
What Schedule 2 and Schedule 3 actually mean
Both categories sit inside Australia's Poisons Standard, the national list that sets how tightly a substance is controlled. The difference is about how the sale happens, not about the substance itself.
Schedule 2, "Pharmacy Medicine": can be sold in the open pharmacy area, without a pharmacist needing to be personally involved in the sale, though pharmacy staff are present. (Healthdirect explainer)
Schedule 3, "Pharmacist Only Medicine": has to be requested from, and supplied personally by, the pharmacist, from behind the counter, not the open shelf. (Healthdirect explainer)
The 2026 proposal is asking to move melatonin from the second category into the first. It is not asking to remove it from pharmacy control altogether.
Common questions
Is melatonin going over the counter in Australia? Not yet, and there's no confirmed date. A proposal to move it to Schedule 2 has been considered by committee, but no interim or final decision has been published as at this update.
What is melatonin Schedule 2 in Australia? Schedule 2 doesn't exist for melatonin yet. It's what the 2026 proposal asks the TGA to create: an open-shelf pharmacy entry for adults 18 and over, replacing the pharmacist-only Schedule 3 entry.
Will melatonin become over the counter in Australia in 2026? Unlikely on current evidence. Comparable recent cases have taken seven to twelve months just to reach an interim decision after committee, before a further consultation and a final decision follow. Late 2026 or 2027 is a more realistic window, and even that is an estimate, not a published date.
Is New Zealand's melatonin rule the same as what Australia is proposing? Close. Both are limited to adults 18 and over, approved products, and set dose and pack limits rather than open access. Australia's proposal mirrors that structure, and the TGA says so directly, but it hasn't been adopted.
Does this change anything I can buy right now? No. What's legal today is set out in full near the top of this page.
A note on Settl
We sell a nightly sleep supplement, so it's worth being upfront: we don't carry melatonin, by choice, not because of this proposal. If you're weighing melatonin against the alternative, why we built Settl without it covers the reasoning. For the fuller picture of what's legally available today, including imports and cost, see Can You Buy Melatonin Over the Counter in Australia?
Settl is the nightly sleep powder behind this blog. One scoop in cold water before bed, built to get you to sleep faster, wake less at 3am, sleep deeper and wake up refreshed. No melatonin. Seven actives, every dose on the label. Packed in Sydney, in a TGA-licensed GMP facility. Start For $69.99, then $89.99 a month, inc. GST. Cancel, pause or skip any time. Or buy a single tub, $99. One-time order. Nothing renews.
Cheers, Roy